Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

ROSEMONT, Ill.--(BUSINESS WIRE)--Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy ...

WALTHAM, Mass., March 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing ...

ProMIS Neurosciences (PMN) announced plans to deliver virtual oral presentations at the 2025 Alzheimer’s and Parkison’s Disease International ...